U.S. markets closed

Karyopharm Therapeutics Inc. (KPTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.8900+0.3700 (+10.51%)
At close: 04:00PM EDT
3.8900 0.00 (0.00%)
After hours: 07:32PM EDT

Karyopharm Therapeutics Inc.

85 Wells Avenue
2nd Floor
Newton, MA 02459
United States
617 658 0600

Full Time Employees385

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard A. Paulson M.B.A.Pres, CEO & Director1.27MN/A1967
Dr. Sharon Shacham M.B.A., Ph.D.Co-Founder & Chairman of Scientific Advisory Board766.54kN/A1970
Mr. Michael P. Mason CPA, M.B.A.Exec. VP, CFO & Treasurer692.39kN/A1975
Mr. Ran Frenkel R.Ph., RPhGlobal Head of Clinical Operations667.87kN/A1969
Dr. Mansoor Raza Mirza M.D.Clinical Consultant, Member of Scientific Advisory Board & Independent Director146.14kN/A1961
Mr. Cameron PetersVP of Fin., Assistant Treasurer & Principal Accounting OfficerN/AN/A1960
Ms. Elhan Webb C.F.A.Sr. VP of Investor RelationsN/AN/AN/A
Mr. Michael J. Mano J.D.Sr. VP, Gen. Counsel & Sec.N/AN/A1977
Mr. James Accumanno J.D.Chief Compliance OfficerN/AN/AN/A
Sarah ConnorsVP of Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Corporate Governance

Karyopharm Therapeutics Inc.’s ISS Governance QualityScore as of March 30, 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.